{"entity":{"id":"nct04651634","kind":"trial","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","aka":[],"tldr":"A phase 2 trial of MIT-001 plus CCRT in head and neck squamous cell carcinoma, run by MitoImmune Therapeutics, active and no longer recruiting.","summary":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients is a phase 2 interventional study registered as NCT04651634 by MitoImmune Therapeutics, with 60 participants enrolled, started 2021-06-21 and due to reach its primary completion in 2025-12-31. Interventions recorded: MIT-001 plus CCRT.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04651634","url":"https://clinicaltrials.gov/study/NCT04651634"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04651634","phase":"2","setting":"A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Locally Advanced HNSCC","sponsor":"MitoImmune Therapeutics","enrolled":60,"outcomes":[]},"route":"/trials/nct04651634/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}]}}